Editorial
Welcome to the Genomic Era
N Engl J Med 2003; 349:996-998September 4, 2003
- Article
To him who devotes his life to science, nothing can give more happiness than increasing the number of discoveries, but his cup of joy is full when the results of his studies immediately find practical applications.
— Louis PasteurThis issue of the Journal includes the last installment in a monthly series on genomic medicine that began in November 2002.1-11 The series has focused on the ways in which the rapidly appearing tools of genomics have already begun to change the practice of medicine. In this issue, for instance, Burke explores how genomics has started to improve our understanding of the biology of health and disease in ways that were never before possible.11 Although the series demonstrates that genomics has indeed begun to change the practice of medicine, it catalogues only the birth of the genomic era and thus no more captures in detail the ultimate effect of genomic medicine than does the examination of a newborn foretell what the mature adult will be like.
If the genomic era can be said to have a precise birth date, it was in the midst of the appearance of the series, on April 14, 2003. That was when the international effort known as the Human Genome Project put a close to the pregenomic era with its announcement (available at http://www.genome.gov/11006929) that it had achieved the last of the project's original goals, the complete sequencing of the human genome. The extent and pace of progress in genomics are suggested by the fact that this achievement occurred 11 days shy of the 50th anniversary of the publication of Watson and Crick's seminal description of the DNA double helix. If science, technology, and medicine have consistently demonstrated anything, it is that they proceed at an ever-quickening pace. That we have gone in the past 50 years from the first description of the structure of our DNA to its complete sequencing gives some indication of how much the impact of genomic medicine on the health care of today's neonates will increase by the time they turn 50 years of age.
However, it is not solely the next 50 years that will witness important advances in genomic medicine. Many such advances have already occurred, including some during the interval since the launch of the Genomic Medicine series. Indeed, one need look no further than the pages of the Journal to see potent additional examples of what has occurred during these past few months: the use of genomics for the rapid identification of newly discovered pathogens such as that involved in the severe acute respiratory syndrome (SARS)12,13; the use of gene-expression profiling to assess prognosis and guide therapy, as in breast cancer14; the use of genotyping to stratify patients according to the risk of a disease, such as the long-QT syndrome15 or myocardial infarction16; the use of genotyping to shed light on the response to certain drugs, such as antiepileptic agents17; and the use of genomic approaches in the design and implementation of new drug therapies, such as imatinib for the hypereosinophilic syndrome,18 and to improve our understanding of the role of specific genes in the causation of common conditions, such as obesity.19,20 During this same brief period, other notable genomics-based advances in our understanding of biology and of health have included the first comprehensive analysis of human chromosome 7,21 clarification of the male-specific region of the human Y chromosome,22 and the identification of the gene responsible for progeria.23
In recent months we have seen not only the promise of the genomic era with respect to medicine, but also its pitfalls. An example of the latter has been the revelation that confusion and misinformation have occasionally accompanied the counseling of persons who undergo screening for mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR) — the gene responsible for cystic fibrosis. Different mutations in CFTR have different effects, leading to a range of phenotypes. Proper interpretation of screening results demands an understanding of the clinical implications of specific genotypes. For example, the relatively common 5T variant leads to the phenotype of classic cystic fibrosis only when it is accompanied by the R117H mutation on the same chromosome arm. However, there have been anecdotal reports of persons who were told that the presence of the 5T variant alone was indicative of a serious risk of cystic fibrosis. There is reason to believe that such problems are not intrinsic to genomic medicine and merely reflect the temporary difficulties of integrating virtually any new form of technology into health care. But this example certainly points out the urgency with which genetic literacy must be achieved among all health care providers. In the genomic age, primum non nocere remains a useful aim.
Genomics provides powerful means of discovering hereditary factors in disease. But even in the genomic era, it is not genes alone but the interplay of genetic and environmental factors that determines phenotype (i.e., health or disease). This point is not new, but it bears repeating. For example, a mutation in CHE1 may be innocuous until a person carrying it is exposed to succinylcholine chloride anesthesia, when it leads to prolonged apnea. Conversely, substantial mutations in phenylalanine hydroxylase inevitably result in the sequelae of classic phenylketonuria, including profound mental retardation, unless the affected newborn is placed on a special diet, in which case essentially normal intellectual development can be expected. Recent reports further expand our knowledge of the complex interactions between genes and the environment. For instance, one such study suggests that common variations in the serotonin-transporter gene influence the likelihood of depression after exposure to stress.24
Since it remains difficult to alter genes in humans (for both technical and ethical reasons), for the next couple of decades we will generally use personalized modifications of the environment, and not of genes, to translate genomics-based knowledge into improvements in health for most of our patients. Clinicians will much more frequently suggest to patients with hereditary hemochromatosis that they avoid iron supplementation than that they consider gene therapy. Women who carry mutations in BRCA2 will profit more from taking tamoxifen than from manipulations of their genotype.
With the end of the pregenomic era in sight, more than 600 experts recently collaborated to produce a vision for the future of genomic research and its applications to biology, health, and society.25 According to that vision, for instance, within a decade or two, it will be possible to sequence anyone's entire genome for a laboratory cost of less than $1,000. If this proves true, one can imagine how not only research, but also clinical care, may change dramatically. However, as is true for so much of the application of genomics, ethical, legal, and social issues complicate this optimistic picture. Unless complex issues regarding the patenting and licensing of gene-based knowledge and techniques are dealt with more successfully than they are today, the “$1,000 genome” will remain a wish, not a reality. Even if the intellectual-property discussions are complex, the math is simple. Assuming that roughly half of the approximately 30,000 human genes are patented, if each patent holder were to charge only $1 per test to license his or her gene, the $1,000 genome would become the $16,000 genome, a very different economic, and thus clinical, reality.
Another social issue, with particular relevance in the United States, is the understandable concern of many patients that obtaining genetic information important to their health care is not worth the risk of discrimination stemming from the use of such information by potential insurers or employers. Although more than 40 states limit employers' and insurers' access to or use of genetic information, many people believe that only the passage of legislation mandating uniform national protection against the misuse of such information will lead to full use of genetic testing. Congressional leaders from both major parties and the current administration have supported such federal legislation, and passage of such legislation is currently closer to reality than ever before. However, until it is enacted and signed into law, the fear of discrimination will remain.
Other social issues require our attention if genomic medicine is to benefit our patients. How should genetic tests be regulated? What, if any, are the appropriate uses of direct-to-consumer marketing of genetic tests? The Internet has recently had a proliferation of genetic-testing sites that feature claims grounded in greed and pseudoscience, rather than in data or reality. How will health care providers and the public distinguish between these and responsible testing services, whether they are available through the Internet or in the hospital?
It would be easy to assume that for the forseeable future the benefits of genomic medicine will accrue only to people in developed countries. However, even in resource-poor regions of the world, genomic approaches can offer dramatic benefits to health, as the publication within the past year of the genomes for Plasmodium falciparum 26 and Anopheles gambiae 27 exemplifies. Nonetheless, another important social issue is the challenge of harnessing this unprecedented opportunity so that genomic medicine benefits all.
While recognizing such challenges, we look forward with curiosity and real hope to the advances of the next 50 years — the first 50 years of the genomic era. As evidenced by the Genomic Medicine series, today's researchers and clinicians have already started to use the power of genomics to improve health, and we anticipate that this is but a hint of the progress to come.
Source Information
From the National Human Genome Research Institute, National Institutes of Health, Bethesda, Md.
- References
References
1
Guttmacher AE ,Collins FS . Genomic medicine -- a primer. N Engl J Med 2002;347:1512-1520
Full Text | Web of Science | Medline2
Burke W . Genetic testing. N Engl J Med 2002;347:1867-1875
Full Text | Web of Science | Medline3
Khoury MJ ,McCabe LL ,McCabe ERB . Population screening in the age of genomic medicine. N Engl J Med 2003;348:50-58
Full Text | Web of Science | Medline4
Weinshilboum R . Inheritance and drug response. N Engl J Med 2003;348:529-537
Full Text | Web of Science | Medline5
Lynch HT ,de la Chapelle A . Hereditary colorectal cancer. N Engl J Med 2003;348:919-932
Full Text | Web of Science | Medline6
Nussbaum RL ,Ellis CE . Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-1364[Erratum, N Engl J Med 2003;348:2588.]
Full Text | Web of Science | Medline7
Staudt LM . Molecular diagnosis of the hematologic cancers. N Engl J Med 2003;248:1777-1785[Erratum, N Engl J Med 2003;348:2588.]
Full Text8
Wooster R ,Weber BL . Breast and ovarian cancer. N Engl J Med 2003;348:2339-2347
Full Text | Web of Science | Medline9
Nabel EG . Cardiovascular disease. N Engl J Med 2003;349:60-72
Full Text | Web of Science | Medline10
Clayton EW . Ethical, legal, and social implications of genomic medicine. N Engl J Med 2003;349:562-569
Full Text | Web of Science | Medline11
Burke W . Genomics as a probe for disease biology. N Engl J Med 2003;349:969-974
Full Text | Web of Science | Medline12
Ksiazek TG ,Erdman D ,Goldsmith CS , et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-1966
Full Text | Web of Science | Medline13
Drosten C ,Gunther S ,Preiser W , et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-1976
Full Text | Web of Science | Medline14
van de Vijver MJ ,He YD ,van 't Veer LJ , et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009
Full Text | Web of Science | Medline15
Priori SG ,Schwartz PJ ,Napolitano C , et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-1874
Full Text | Web of Science | Medline16
Yamada Y ,Izawa H ,Ichihara S , et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002;347:1916-1923
Full Text | Web of Science | Medline17
Siddiqui A ,Kerb R ,Weale ME , et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348:1442-1448
Full Text | Web of Science | Medline18
Cools J ,DeAngelo DJ ,Gotlib J , et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214
Full Text | Web of Science | Medline19
Farooqi IS ,Keogh JM ,Yeo GSH ,Lank EJ ,Cheetham E ,O'Rahilly S . Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-1095
Full Text | Web of Science | Medline20
Branson R ,Potoczna N ,Kral JG ,Lentes K-U ,Hoehe MR ,Horber FF . Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 2003;348:1096-1103
Full Text | Web of Science | Medline21
Hillier LW ,Fulton RS ,Fulton LA , et al. The DNA sequence of human chromosome 7. Nature 2003;424:157-164
CrossRef | Web of Science | Medline22
Skaletsky H ,Kuroda-Kawaguchi T ,Minx PJ , et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature 2003;423:825-837
CrossRef | Web of Science | Medline23
Erikkson M ,Brown WT ,Gordon LB , et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003;423:293-298
CrossRef | Web of Science | Medline24
Caspi A ,Sugden K ,Moffitt TE , et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301:386-389
CrossRef | Web of Science | Medline25
Collins FS ,Green ED ,Guttmacher AE ,Guyer MS . A vision for the future of genomics research. Nature 2003;422:835-847
CrossRef | Web of Science | Medline26
Gardner MJ ,Hall N ,Fung E , et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002;419:498-511
CrossRef | Web of Science | Medline27
Holt RA ,Subramanian GM ,Halpern A , et al. The genome sequence of the malaria mosquito Anopheles gambiae. Science 2002;298:129-149
CrossRef | Web of Science | Medline
- Citing Articles (70)
Citing Articles
1
Alison Harvey. (2011) From lab to lifestyle: translating genomics into healthcare practices. New Genetics and Society 30:4, 309-327
CrossRef2
G. A. Lanza, G. Scalone, L. Barone, F. Infusino, I. Coviello, A. Di Monaco, A. Delogu, I. Battipaglia, A. De Nisco, A. Sestito, C. Romagnoli, F. Crea. (2011) Platelet reactivity and endothelial function in children of patients with early acute myocardial infarction. European Heart Journal 32:16, 2042-2049
CrossRef3
Simona Lucia Bavaro, Michele Calabrò, Darja Kanduc. (2011) Pentapeptide sharing between Corynebacterium diphtheria toxin and the human neural protein network. Immunopharmacology and Immunotoxicology 33:2, 360-372
CrossRef4
Juping Yu, Nicki Taverner, Kim Madden. (2011) Young people’s views on sharing health-related stories on the Internet. Health & Social Care in the Community 19:3, 326-334
CrossRef5
Edwin B. Fisher, Marian L. Fitzgibbon, Russell E. Glasgow, Debra Haire-Joshu, Laura L. Hayman, Robert M. Kaplan, Marilyn S. Nanney, Judith K. Ockene. (2011) Behavior Matters. American Journal of Preventive Medicine 40:5, e15-e30
CrossRef6
S. Ashida, M. Goodman, C. Pandya, L.M. Koehly, C. Lachance, J. Stafford, K.A. Kaphingst. (2011) Age Differences in Genetic Knowledge, Health Literacy and Causal Beliefs for Health Conditions. Public Health Genomics 14:4-5, 307-316
CrossRef7
Paul G. Sanfilippo, Alex W. Hewitt, Chris J. Hammond, David A. Mackey. (2010) The Heritability of Ocular Traits. Survey of Ophthalmology 55:6, 561-583
CrossRef8
François Rousseau, Carmen Lindsay, Marc Charland, Yves Labelle, Jean Bergeron, Ingeborg Blancquaert, Robert Delage, Brian Gilfix, Michel Miron, Grant A. Mitchell, Luc Oligny, Mario Pazzagli, Cyril Mamotte, Deborah Payne. (2010) Development and description of GETT: a Genetic testing Evidence Tracking Tool. Clinical Chemistry and Laboratory Medicine 48:10, 1397-1407
CrossRef9
K. C. Koenen, M. Uddin, A. B. Amstadter, S. Galea. (2010) Incorporating the social environment in genotype environment interaction studies of mental disorders. International Journal of Clinical Practice 64:11, 1489-1492
CrossRef10
Christina R. Lachance, Lori A. H. Erby, Beth M. Ford, Vincent C. Allen, Kimberly A. Kaphingst. (2010) Informational content, literacy demands, and usability of websites offering health-related genetic tests directly to consumers. Genetics in Medicine 12:5, 304-312
CrossRef11
Alison Harvey. (2010) Genetic risks and healthy choices: creating citizen-consumers of genetic services through empowerment and facilitation. Sociology of Health & Illness 32:3, 365-381
CrossRef12
Jeffrey R. Botkin, Steven M. Teutsch, Celia I. Kaye, Maxine Hayes, James E. Haddow, Linda A. Bradley, Kathleen Szegda, W. David Dotson. (2010) Outcomes of interest in evidence-based evaluations of genetic tests. Genetics in Medicine1
CrossRef13
Michaela J. Higgins, Vered Stearns. (2010) CYP2D6 Polymorphisms and Tamoxifen Metabolism: Clinical Relevance. Current Oncology Reports 12:1, 7-15
CrossRef14
Lynn Rew, Michael Mackert, Daniel Bonevac. (2009) A Systematic Review of Literature About the Genetic Testing of Adolescents. Journal for Specialists in Pediatric Nursing 14:4, 284-294
CrossRef15
Jill Waalen, Ernest Beutler. (2009) Genetic Screening for Low-Penetrance Variants in Protein-Coding Genes. Annual Review of Genomics and Human Genetics 10:1, 431-450
CrossRef16
Georgios Voidonikolas, Stephanie S. Kreml, Changyi Chen, William E. Fisher, F. Charles Brunicardi, Richard A. Gibbs, Marie-Claude Gingras. (2009) Basic Principles and Technologies for Deciphering the Genetic Map of Cancer. World Journal of Surgery 33:4, 615-629
CrossRef17
Owen A. Ross, James F. Meschia. (2009) Genetics of ischemic stroke: Inheritance of a sporadic disorder. Current Neurology and Neuroscience Reports 9:1, 19-27
CrossRef18
John M. Quillin, Judy Silberg, Resa M. Jones, Diane Baer Wilson, Hermine Maes, Deborah Bowen, Joann Bodurtha. (2008) Tolerance for ambiguity could influence awareness of breast cancer genetic testing and inform health education. Cancer Causes & Control 19:10, 1227-1232
CrossRef19
Maggie Kirk, Dale Lea, Heather Skirton. (2008) Genomic health care: Is the future now?. Nursing & Health Sciences 10:2, 85-92
CrossRef20
Kjetil Rommetveit. (2008) Towards a hermeneutic of technomedical objects. Theoretical Medicine and Bioethics 29:2, 103-120
CrossRef21
John Lynch, Jennifer Bevan, Paul Achter, Tina Harris, Celeste M. Condit. (2008) A preliminary study of how multiple exposures to messages about genetics impact on lay attitudes towards racial and genetic discrimination. New Genetics and Society 27:1, 43-56
CrossRef22
Eduard Guzmán, Antoni Romeu, Santiago Garcia-Vallve. (2008) Completely sequenced genomes of pathogenic bacteria: A review. Enfermedades Infecciosas y Microbiología Clínica 26:2, 88-98
CrossRef23
Fotini K. Kavvoura, John P. A. Ioannidis. (2008) Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Human Genetics 123:1, 1-14
CrossRef24
Suzanne C. O’Neill, Della Brown White, Saskia C. Sanderson, Isaac M. Lipkus, Gerold Bepler, Lori A. Bastian, Colleen M. McBride. (2008) The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. Genetics in Medicine 10:2, 121-130
CrossRef25
Udo Seedorf, Helmut Schulte, Gerd Assmann. (2007) Genes, diet and public health. Genes & Nutrition 2:1, 75-80
CrossRef26
John M. Quillin. (2007) Book review: Building genetic medicine: Breast cancer, technology, and the comparative politics of health care. American Journal of Human Biology 19:5, 737-739
CrossRef27
Robyn H Guymer. (2007) 2006 Council Lecture: Lancelot to the rescue: realizing the promise of genomic medicine. Clinical & Experimental Ophthalmology 35:5, 403-408
CrossRef28
J. P. A. Ioannidis. (2007) Molecular evidence-based medicine.. European Journal of Clinical Investigation 37:5, 340-349
CrossRef29
Jean Jenkins, Kathleen A. Calzone. (2007) Establishing the Essential Nursing Competencies for Genetics and Genomics. Journal of Nursing Scholarship 39:1, 10-16
CrossRef30
Charles D. Collard. (2007) ???A Razor May Be Sharper Than an Ax, but It Cannot Cut Wood???. Anesthesiology 106:3, 420-422
CrossRef31
D Ghosh, M A Skinner, W A Laing. (2007) Pharmacogenomics and nutrigenomics: synergies and differences. European Journal of Clinical Nutrition
CrossRef32
Ahmed I. Gilani, Atif S. Jadoon, Rabia Qaiser, Sana Nasim, Riffat Meraj, Nosheen Nasir, Fizza F. Naqvi, Zafar Latif, Muhammad A. Memon, Esme V. Menezes, Imran Malik, Muhammad Z. Memon, Syed F. Kazim, Usman Ahmad. (2007) Attitudes towards Genetic Diagnosis in Pakistan: A Survey of Medical and Legal Communities and Parents of Thalassemic Children. Community Genetics 10:3, 140-146
CrossRef33
Muin J. Khoury, Roberto Romero. (2006) The integration of genomics into obstetrics and gynecology: A HuGE challenge. American Journal of Obstetrics and Gynecology 195:6, 1503-1505
CrossRef34
Kathleen A. Calzone, Dale Halsey Lea, Agnes Masny. (2006) Non-Hodgkin's Lymphoma as an Exemplar of the Effects of Genetics and Genomics. Journal of Nursing Scholarship 38:4, 335-343
CrossRef35
Kari Hemminki, Justo Lorenzo Bermejo, Asta Försti. (2006) The balance between heritable and environmental aetiology of human disease. Nature Reviews Genetics 7:12, 958-965
CrossRef36
Roger T. Anderson, Lari Wenzel, Ann P. Walker, Andrea Ruggiero, Ronald T. Acton, Mark A. Hall, Diane C. Tucker, Elizabeth Thomson, Barbara Harrison, Edmund Howe, Joan Holup, Catherine Leiendecker-Foster, Tara Power, Paul Adams. (2006) Impact of hemochromatosis screening in patients with indeterminate results: The hemochromatosis and iron overload screening study. Genetics in Medicine 8:11, 681-687
CrossRef37
David Seo, Geoffrey S. Ginsburg, Pascal J. Goldschmidt-Clermont. (2006) Gene Expression Analysis of Cardiovascular Diseases. Journal of the American College of Cardiology 48:2, 227-235
CrossRef38
Terrie E. Moffitt, Avshalom Caspi, Michael Rutter. (2006) Measured Gene-Environment Interactions in Psychopathology. Concepts, Research Strategies, and Implications for Research, Intervention, and Public Understanding of Genetics. Perspectives on Psychological Science 1:1, 5-27
CrossRef39
Gregory J. Tsongalis, William B. Coleman. (2006) Clinical genotyping: The need for interrogation of single nucleotide polymorphisms and mutations in the clinical laboratory. Clinica Chimica Acta 363:1-2, 127-137
CrossRef40
Karmen Stankov. (2006) Diagnostics of hereditary malignancies. Jugoslovenska medicinska biohemija 25:4, 381-390
CrossRef41
Christine T. Finn, Jordan W. Smoller. (2006) Genetic Counseling in Psychiatry. Harvard Review of Psychiatry 14:2, 109-121
CrossRef42
Cathy Fomous, Joyce A. Mitchell, Alexa McCray. (2006) ‘Genetics Home Reference’: Helping Patients Understand the Role of Genetics in Health and Disease. Community Genetics 9:4, 274-278
CrossRef43
Karmen Stankov. (2006) Diagnostics of hereditary malignancies. Jugoslovenska medicinska biohemija 25:4, 381-390
CrossRef44
Robert J. McCunney. (2005) Asthma, Genes, and Air Pollution. Journal of Occupational and Environmental Medicine 47:12, 1285-1291
CrossRef45
Levy, Harvey L., . (2005) Metabolic Disorders in the Center of Genetic Medicine. New England Journal of Medicine 353:18, 1968-1970
Full Text46
Konstantinos N. Lazaridis, Brian D. Juran. (2005) American Gastroenterological Association Future Trends Committee Report: The Application of Genomic and Proteomic Technologies to Digestive Disease Diagnosis and Treatment and Their Likely Impact on Gastroenterology Clinical Practice. Gastroenterology 129:5, 1720-1752
CrossRef47
Hong-Guang Xie, Felix W Frueh. (2005) Pharmacogenomics steps toward personalized medicine. Personalized Medicine 2:4, 325-337
CrossRef48
Roger T. Anderson, Nancy Press, Diane C. Tucker, Beverly M. Snively, Lari Wenzel, Shellie D. Ellis, Mark A. Hall, Ann P. Walker, Elizabeth J. Thomson, Ometha Lewis-Jack, Ronald T. Acton. (2005) Patient acceptability of genotypic testing for hemochromatosis in primary care. Genetics in Medicine 7:8, 557-563
CrossRef49
Heather Skirton, Evelyn Parsons, Paul Ewings. (2005) Development of an audit tool for genetic services. American Journal of Medical Genetics Part A 136A:2, 122-127
CrossRef50
(2005) Informational Paper: Implications of Genetic Technology for the Management of Periodontal Diseases. Journal of Periodontology 76:5, 850-857
CrossRef51
Muin J. Khoury. (2005) The integration of genomics into paediatric and perinatal epidemiology: guidelines for submitting human genome epidemiology (HuGE) reviews. Paediatric and Perinatal Epidemiology 19:3, 178-180
CrossRef52
JC Biro, Z Benyó, C Sansom, B Benyó. (2005) In search of the nature of specific nucleic acid-protein interactions. Acta Physiologica Hungarica 92:1, 1-10
CrossRef53
Tze Kin Lau, Tse Ngong Leung. (2005) Genetic screening and diagnosis. Current Opinion in Obstetrics and Gynecology 17:2, 163-169
CrossRef54
Michael J. Malinowski. (2005) Technology Transfer in BioBanking: Credits, Debits, and Population Health Futures. The Journal of Law, Medicine & Ethics 33:1, 54-69
CrossRef55
R. P. Ojha, R. Thertulien. (2005) Health Care Policy Issues as a Result of the Genetic Revolution: Implications for Public Health. American Journal of Public Health 95:3, 385-388
CrossRef56
Tischa J. M. van der Cammen, Esther A. Croes, Bart Dermaut, Marie-Claire de Jager, Marc Cruts, Christine Van Broeckhoven, Cornelia M. Van Duijn. (2004) Genetic Testing Has No Place as a Routine Diagnostic Test in Sporadic and Familial Cases of Alzheimer's Disease. Journal of the American Geriatrics Society 52:12, 2110-2113
CrossRef57
Nathaniel H Robin. (2004) Genetic testing will bring interesting times to clinical practice. Current Opinion in Pediatrics 16:6, 667-669
CrossRef58
Barbara J Evans, David A Flockhart, Eric M Meslin. (2004) Creating incentives for genomic research to improve targeting of therapies. Nature Medicine 10:12, 1289-1291
CrossRef59
Jose M. Ordovas, Dolores Corella. (2004) NUTRITIONAL GENOMICS. Annual Review of Genomics and Human Genetics 5:1, 71-118
CrossRef60
Richard Weinshilboum, Liewei Wang. (2004) Pharmacogenomics: bench to bedside. Nature Reviews Drug Discovery 3:9, 739-748
CrossRef61
CARL E. HUNT. (2004) Genes and Sudden Infant Death Syndrome. Pediatric Research 56:3, 321-322
CrossRef62
Christina L. Aquilante, Maximilian T. Lobmeyer, Taimour Y. Langaee, Julie A. Johnson. (2004) Comparison of Cytochrome P450 2C9 Genotyping Methods and Implications for the Clinical Laboratory. Pharmacotherapy 24:6, 720-726
CrossRef63
Jose D Debes, Raul Urrutia. (2004) Bioinformatics tools to understand human diseases. Surgery 135:6, 579-585
CrossRef64
E. S. J. M. Bont, G. H. Koppelman. (2004) Genpolymorfismen in de kindergeneeskundige praktijk. Tijdschrift voor kindergeneeskunde 72:2, 49-52
CrossRef65
CR Scriver. (2004) Translating knowledge into practice in the “post-genome” era*. Acta Paediatrica 93:3, 294-300
CrossRef66
Stephan Ziegeler, Byron E. Tsusaki, Charles D. Collard. (2004) Genetic Markers: Not Yet Ready for Prime Time: In Reply. Anesthesiology 100:2, 458-459
CrossRef67
Christopher P. Austin. (2004) The Impact of the Completed Human Genome Sequence on the Development of Novel Therapeutics for Human Disease*. Annual Review of Medicine 55:1, 1-13
CrossRef68
Jason M Langheier, Ralph Snyderman. (2004) Prospective medicine: the role for genomics in personalized health planning. Pharmacogenomics 5:1, 1-8
CrossRef69
Theresa A. Beery, Marcia J. Hern. (2004) Genetic Practice, Education, and Research. Clinical Nurse Specialist 18:3, 126-132
CrossRef70
(2003) Genomic Medicine. New England Journal of Medicine 349:22, 2170-2171
Full Text
- Letters
